Description
Summary Abstract
Epithalon (Epitalon; AEDG tetrapeptide; Ala-Glu-Asp-Gly; C14H22N4O9; MW 390.35 g/mol; CAS 307297-39-8; PubChem CID 219042) is a synthetic tetrapeptide corresponding to the amino acid sequence Alanine-Glutamic Acid-Aspartic Acid-Glycine (AEDG), originally synthesized as the bioactive core of Epithalamin — a crude polypeptide extract from bovine pineal glands developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Confirmed in 2017 as an endogenous, naturally occurring pineal peptide, Epithalon is classified as a peptide bioregulator proposed to act as a master epigenetic regulator of aging-associated gene expression. Its most extensively studied mechanism is the activation of telomerase: in vitro studies in human fetal fibroblasts demonstrated induced hTERT (human Telomerase Reverse Transcriptase) expression, functional telomerase activity, telomere elongation, and a >25% extension of replicative lifespan beyond the Hayflick limit. Secondary mechanisms include restoration of nocturnal melatonin synthesis and circadian cortisol rhythms in senescent primates (Epithalon 2001 primate study), and direct interaction with histone proteins H1/3 and H1/6 to remodel chromatin structure and reactivate silenced genes. Long-term Epithalamin extract trials in elderly patients with cardiovascular disease reported 28% reduced all-cause mortality and 2-fold reduced cardiovascular mortality over 12 years; these findings originate from a single Russian research group and lack independent international replication. FDA Orphan Drug designation for Epitalon in retinitis pigmentosa was granted in 2010 and subsequently withdrawn in 2016.
Clinical Indications
Epithalon’s proposed applications span gerontology, neuroprotection, and regenerative medicine:
- Geroprotection / Cellular Lifespan Extension: In vitro: >25% extension of human fibroblast replicative lifespan via telomerase activation; in vivo: 11–16% lifespan extension in Drosophila; 20–40% in rodent long-term studies.
- Cardiovascular and All-Cause Mortality Reduction: A 12-year Epithalamin extract trial in elderly patients with cardiovascular disease reported 28% reduction in all-cause mortality and 2-fold reduction in cardiovascular mortality versus background therapy.
- Retinitis Pigmentosa (Targeted Epitalon Trial): Parabulbar injection of Epithalon (5 µg daily × 10 days) produced positive clinical effect in 90% of patients with degenerative retinal lesions, including improved visual acuity and expanded peripheral visual field.
- Neuroendocrine Restoration: Restored the blunted nocturnal melatonin peak and dysregulated cortisol circadian rhythm in aged senescent monkeys, providing a neuroendocrine rationale for sleep-quality and stress-resilience applications.
Contraindications
- Active or History of Malignancy (Theoretical Telomerase Risk): Telomerase activation is the primary mechanism of Epithalon; since ~85–90% of human cancers rely on telomerase for replicative immortality, systemic use in patients with confirmed or occult neoplasia carries a theoretical risk of promoting tumor cell proliferation, despite paradoxical anti-tumor findings in animal studies.
- Immunogenicity Risk: The FDA has raised concerns about potential immunogenicity of synthetic peptides like Epithalon in clinical contexts; monitoring for hypersensitivity reactions is advisable.
- Pregnancy: No safety data; avoid use during pregnancy or breastfeeding.
Mechanism of Action (MOA)
Epithalon operates through four proposed, mechanistically interconnected pathways that collectively target the fundamental biology of cellular aging:
Telomerase Activation — hTERT Induction and Telomere Elongation
Epithalon’s most studied mechanism is the activation of telomerase. In vitro studies in telomerase-negative human fetal fibroblasts demonstrated that AEDG induces hTERT mRNA expression, restoring functional telomerase enzymatic activity that elongates critically short telomeres. Treated cells exceeded their normal Hayflick limit by >25% additional population doublings (34 passages in controls vs. >44 in treated cells). This mechanism addresses the progressive telomere shortening that drives replicative senescence.
Neuroendocrine Regulation — Pineal Melatonin and Cortisol Rhythm
As a peptide bioregulator of the pineal gland, Epithalon restores the blunted nocturnal melatonin synthesis peak observed in aged primates, normalizing the circadian rhythm of melatonin and correcting the dysregulated cortisol profile that accompanies pineal aging. Melatonin restoration supports sleep architecture, antioxidant defense, and systemic hormonal homeostasis. Evidence is consistent in primate models but conflicting in some rodent studies, possibly reflecting species-specific pineal physiology.
Epigenetic Chromatin Remodeling — Histone Binding and Heterochromatin Decondensation
Molecular modeling and experimental data propose that AEDG binds directly to histone proteins H1/3 and H1/6, inducing decondensation of pericentromeric heterochromatin in human lymphocytes from elderly donors. This “un-tightening” of compacted chromatin reactivates age-silenced genes involved in neurogenesis (Nestin, GAP43 upregulation in mesenchymal stem cells), immune function (IL-2 modulation), and tumor suppression (HER-2/neu downregulation 3.7-fold in transgenic mice). This epigenetic mechanism may unify the diverse downstream effects attributed to the peptide.
Antioxidant, Anti-Senescence, and Immunomodulatory Activity
Epithalon reduces reactive oxygen species (ROS) and lipid peroxidation, and stimulates endogenous antioxidant enzymes (superoxide dismutase). It inhibits matrix metalloproteinase-9 (MMP-9) in aging skin fibroblasts — a key SASP (Senescence-Associated Secretory Phenotype) component that degrades collagen and promotes inflammatory tissue remodeling. Immunomodulatory effects include restoration of T-cell proliferation in the thymus and increased lymphocyte function, countering immunosenescence.
Key Features & Specifications
Structural and pharmacological profile of Epithalon:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG; 4 amino acids) |
| CAS Number | 307297-39-8 |
| Molecular Formula | C14H22N4O9 |
| Molecular Weight | 390.35 g/mol |
| PubChem CID | 219042 |
| Synonyms | Epitalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly |
| Form / Variation | 10 MG Lyophilized (P-009) |
Storage, Safety, and Handling
Storage Protocol
Store lyophilized Epithalon at −20 °C in sealed containers, protected from light and moisture; stable ≥24 months. Once reconstituted with sterile water for injection, stable at 2–8 °C for 14 days. The small tetrapeptide has excellent chemical stability but remains susceptible to proteolysis in biological fluids; the short sequence (4 amino acids) provides relative resistance versus longer peptides.
Handling & Compliance
Handle under aseptic conditions with standard PPE. Long-term animal studies reported no adverse findings at pharmacologically active doses, and the Epithalamin extract trials in elderly humans reported no severe adverse events over 3-year treatment periods. Administration routes studied include subcutaneous and parabulbar injection; oral bioavailability has not been formally established. Neither Epithalon nor Epithalamin is FDA- or EMA-approved as a medicinal product; FDA Orphan Drug designation for retinitis pigmentosa was withdrawn in 2016. Comprehensive modern Phase I safety data are not available.